Apitegromab preserves lean mass during tirzepatide weight loss in phase 2

The wire

1. 01Adults with overweight or obesity were randomized 1:1 to tirzepatide plus apitegromab 10 mg/kg or tirzepatide plus placebo; at week 24 the antibody group lost 1.9 kg less lean mass (P = 0.001), a 54.9% relative retention.
2. 02Lean mass loss on incretin therapy is a live clinical concern, and this is proof-of-concept human data on a combination approach rather than diet or resistance training alone.
3. 03Adverse events were similar between arms (76% versus 71%) with one serious event in each, but the study was a 102-patient phase 2 with no functional outcomes reported.

From the source

Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial

Loss of lean mass in proportion to total weight loss is observed with incretin mimetic therapies such as tirzepatide and has the potential to adversely affect health and function. Apitegromab is an investigational, fully human monoclonal antibody that selectively inhibits myostatin activation and is, thereby, capable of increasing muscle mass. In the randomized, double-blind, placebo-controlled ph